Pharmaceutical company Alvogen revealed on Wednesday the availability of its generic equivalent of Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the US in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg and 12mg/3mg strengths.
The company said the Suboxone sublingual film is indicated for treatment of opioid dependence.
Based on Indivior SEC Filings, the US sales for Suboxone were approximately USD1.1bn in 2018.
Suboxone, which is a registered trademark of Indivior UK LLC, follows the issuance of a mandate from the US Court of Appeals for the Federal Circuit vacating the preliminary injunction that had been granted enjoining Dr. Reddy's Laboratories from marketing its product.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)